FDA issues statement on the agency’s ongoing efforts to resolve safety issue with ARB medications – Drug Information Update

https://www.fda.gov/news-events/press-announcements/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications?utm_campaign=FDA%20issues%20statement%20on%20the%20agency%E2%80%99s%20ongoing%20efforts%20to%20resolve%20safety%20issue%20with%20ARB%20medications&utm_medium=email&utm_source=Eloqua


FDA issues statement on the agency's ongoing efforts to resolve safety issue with ARB medications

Protecting patients is the FDA’s highest priority, and Americans can be confident in the quality of the products the agency approves. The recent Angiotensin II Receptor Blocker (ARB) recalls have deeply concerned patients, the medical community, the agency and international regulatory bodies. The FDA is aware many patients rely on ARB medicines, and we are concerned about the presence of nitrosamine impurities in these drugs. Millions of people benefit from the high-quality products that the FDA regulates, and the U.S. has the most robust drug supply in the world, with strict standards for safety, effectiveness and quality.

As part of our efforts to be transparent regarding impurities in ARBs, we want to make sure patients have a full understanding of how these impurities may affect them.

For more information, please visit: Statement on the ongoing efforts to resolve safety issue with ARBs.